Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Masimo Corporation is a global medical technology company specializing in innovative monitoring technologies, including sensors and patient monitors, primarily serving the healthcare sector. The company is renowned for its Masimo SET pulse oximetry technology, widely used in hospitals worldwide.
In its third-quarter 2025 earnings report, Masimo Corporation reported robust growth, with GAAP revenue reaching $371.5 million, marking an 8.2% increase. The company also highlighted a significant improvement in its net income per diluted share, which rose to $0.99 on a GAAP basis and $1.32 on a non-GAAP basis, reflecting a 38% growth compared to the previous year.
Key financial metrics from the report include an 8% increase in revenues, a 450 basis point improvement in operating margin, and a strategic move involving the sale of Sound United to Harman. The proceeds from this sale were utilized for stock repurchase, demonstrating the company’s focus on enhancing shareholder value. Additionally, Masimo expanded its strategic partnership with Philips, indicating a commitment to long-term growth and innovation in its core healthcare business.
Looking ahead, Masimo Corporation has provided an optimistic outlook for the remainder of 2025, projecting non-GAAP revenue to range between $1,510 million and $1,530 million, with an operating margin of up to 28.8%. The company remains focused on leveraging its innovative products and strategic partnerships to drive sustainable growth in the healthcare sector.